SciRhom GmbH is a therapeutic antibody company developing first-in-class antibodies against iRhom2, a key modulator of several major pro-inflammatory signaling pathways, including TNF-alpha signaling. Based on a decade of cutting-edge bench research and the completion of a challenging, yet ultimately successful antibody campaign, SciRhom is now in the unique position to pursue the development of monoclonal antibodies against iRhom2 for the treatment of major autoimmune diseases.
Location: Germany, Bavaria, Martinsried
Total raised: $68.13M
Investors 1
| Date | Name | Website |
| 17.07.2021 | High-Tech ... | htgf.de |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 09.07.2024 | Series A | $68.13M | - |
Mentions in press and media 5
| Date | Title | Description |
| 12.07.2024 | SciRhom's Groundbreaking Series A Financing | SciRhom, a Munich-based biopharmaceutical company, recently secured a whopping EUR 63 million in Series A funding. The round was co-led by top investors like Andera Partners, Kurma Partners, Hadean Ventures, MIG Capital, and Wellington Part... |
| 09.07.2024 | SciRhom Secures EUR 63 Million Series A Financing Round to Accelerate iRhom2-targeting Therapies in Autoimmune Diseases | The upsized and oversubscribed Series A financing round will be used to drive the lead development program toward clinical proof-of-concept and to broaden the therapeutic value of the proprietary iRhom2 strategy. Munich, Germany, July 9, 20... |
| 09.07.2024 | SciRhom Raises EUR 63M in Series A Financing | SciRhom, a Munich, Germany-based biopharmaceutical company developing therapeutic iRhom2 antibodies, raised EUR 63M in Series A funding. The round was co-led by Andera Partners, Kurma Partners, Hadean Ventures, MIG Capital, and Wellington P... |
| 01.12.2021 | SciRhom augments seed financing to reach total funding of 16 million euros | The Martinsried-based company SciRhom was able to increase its seed capital to a total of EUR 16 million in another seed financing round. This support is expected to help reach the next development milestones of the novel antibody therapy a... |
| - | SciRhom | “Home - SciRhom GmbH” |